JP7839789B2 - オピオイド治療用抗体 - Google Patents

オピオイド治療用抗体

Info

Publication number
JP7839789B2
JP7839789B2 JP2023527344A JP2023527344A JP7839789B2 JP 7839789 B2 JP7839789 B2 JP 7839789B2 JP 2023527344 A JP2023527344 A JP 2023527344A JP 2023527344 A JP2023527344 A JP 2023527344A JP 7839789 B2 JP7839789 B2 JP 7839789B2
Authority
JP
Japan
Prior art keywords
seq
antibody
sequence
amino acid
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023527344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548603A (ja
JP2023548603A5 (https=
Inventor
ジャンダ，キム・ディー．
ブレマー，ポール・ティー．
ジョウ，ビン
Original Assignee
ザ スクリプス リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スクリプス リサーチ インスティテュート filed Critical ザ スクリプス リサーチ インスティテュート
Publication of JP2023548603A publication Critical patent/JP2023548603A/ja
Publication of JP2023548603A5 publication Critical patent/JP2023548603A5/ja
Application granted granted Critical
Publication of JP7839789B2 publication Critical patent/JP7839789B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Addiction (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023527344A 2020-11-10 2021-11-08 オピオイド治療用抗体 Active JP7839789B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063111699P 2020-11-10 2020-11-10
US63/111,699 2020-11-10
PCT/US2021/058459 WO2022103700A1 (en) 2020-11-10 2021-11-08 Antibodies for opioid treatments

Publications (3)

Publication Number Publication Date
JP2023548603A JP2023548603A (ja) 2023-11-17
JP2023548603A5 JP2023548603A5 (https=) 2024-10-17
JP7839789B2 true JP7839789B2 (ja) 2026-04-02

Family

ID=81601678

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023527344A Active JP7839789B2 (ja) 2020-11-10 2021-11-08 オピオイド治療用抗体

Country Status (10)

Country Link
US (1) US20230399418A1 (https=)
EP (1) EP4244256A4 (https=)
JP (1) JP7839789B2 (https=)
KR (1) KR20230107301A (https=)
CN (1) CN116745318A (https=)
AU (1) AU2021377609A1 (https=)
CA (1) CA3200523A1 (https=)
IL (1) IL302673A (https=)
MX (1) MX2023005032A (https=)
WO (1) WO2022103700A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3267132A1 (en) * 2022-09-09 2024-03-14 Regents Of The University Of Minnesota ANTIBODIES DIRECTED AGAINST FENTANYL AND ITS ANALOGUES AND THEIR METHODS OF USE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200808822A (en) * 2006-04-14 2008-02-16 Amgen Inc Erythropoietin receptor agonists
WO2013095091A2 (en) * 2011-11-17 2013-06-27 Aimm Therapeutics B.V. Rsv g protein specific antibodies
AU2017345786B2 (en) * 2016-10-21 2024-08-01 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
WO2018140821A1 (en) * 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
EP3880698A4 (en) * 2018-11-14 2022-11-30 RubrYc Therapeutics, Inc. MANIPULATED CD25 POLYPEPTIDES AND USES THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of the American Chemical Society，米国，2019年，141(26):10489-10503

Also Published As

Publication number Publication date
WO2022103700A1 (en) 2022-05-19
MX2023005032A (es) 2023-05-16
CN116745318A (zh) 2023-09-12
KR20230107301A (ko) 2023-07-14
US20230399418A1 (en) 2023-12-14
EP4244256A4 (en) 2024-12-25
AU2021377609A1 (en) 2023-06-08
IL302673A (en) 2023-07-01
CA3200523A1 (en) 2022-05-19
JP2023548603A (ja) 2023-11-17
AU2021377609A9 (en) 2024-09-26
EP4244256A1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
JP7682335B2 (ja) オンコスタチンｍ受容体抗原結合タンパク質
JP6114326B2 (ja) 組織因子経路阻害因子に対する抗体
JP7391510B2 (ja) ヒト化抗ｃｄ７３抗体
EP3689370B1 (en) Anti-gdf15 antibodies
JP6437922B2 (ja) Ｂｃｍａ抗原結合タンパク質
JP2022514693A (ja) Ｍｕｃ１８に特異的な抗体
JP7607564B2 (ja) Ｐｍｅｌ１７に対する抗体及びその結合体
KR102132604B1 (ko) 비형 간염 표면 항원에 대한 항체 및 그의 용도
EP2935330B1 (en) Anti-notch3 antibodies
JP7839789B2 (ja) オピオイド治療用抗体
KR20220066295A (ko) 항트립타제 항체의 투약
TW202108631A (zh) 一種抗ｃｄ４７抗原結合蛋白及其應用
RU2841257C1 (ru) Антитела для лечения опиоидной зависимости
JP7649756B2 (ja) 抗ａｎｇｐｔ２抗体
JP2024534004A (ja) 抗トリプターゼ抗体のための投与量
JP2024505195A (ja) 抗ｐｄｇｆ－ｂ抗体及び肺動脈高血圧症（ｐａｈ）を治療するための使用方法
JP5963233B2 (ja) Ｈｔｌｖ−１関連脊髄症を治療または予防するための医薬および前記医薬を用いた抗体療法の治療効果の確認方法
CN115197323A (zh) 一种sn38抗体或其抗原结合片段及其应用
AU2022303422B2 (en) Anti-gfral antibody and application thereof
WO2024112561A1 (en) Methods for the treatment of myasthenia gravis
HK40112252A (en) Antibodies to pmel17 and conjugates thereof
KR20260046391A (ko) 항-ror1 단백질 항체 및 이의 접합체
CN121005780A (zh) 靶向hla-g的抗体或其抗原结合片段及其应用
HK40067775A (en) Dosing for anti-tryptase antibodies
EA047046B1 (ru) Антитела к angpt2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241008

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241008

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260323

R150 Certificate of patent or registration of utility model

Ref document number: 7839789

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150